Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGFRL1 | Q5TC84 | 20/20 | 0.77 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 16/20 | 0.77 |
| ▸ | OPRD1 | P41143 | 13/20 | 0.77 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22622305 | 0.87 | OGFRL1 (0.81) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| Sunobinop SCHEMBL852621 | 0.87 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| Sunobinop SCHEMBL852622 | 0.87 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| Sunobinop SCHEMBL31502988 | 0.87 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL880392 | 0.87 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| Sunobinop SCHEMBL21366378 | 0.87 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| Sunobinop SCHEMBL22622383 | 0.87 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL854158 | 0.87 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL852111 | 0.87 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| Sunobinop SCHEMBL12345477 | 0.87 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293516-A1 | SLEEP DISORDER TREATMENT AND PREVENTION | PURDUE PHARMA L.P. (US) | 2023-09-21 | — | — | US | disclosed |
| US-11738023-B2 | Treatment and prevention of sleep disorders | PURDUE PHARMA L.P. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210330994-A1 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | PURDUE PHARMA L.P. (US) | 2021-10-28 | — | — | US | disclosed |
| WO-2019145850-A1 | SLEEP DISORDER TREATMENT AND PREVENTION | PURDUE PHARMA L. P. (US) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11738023-B2 | Treatment and prevention of sleep disorders | HCRTR1, HCRTR2, MTNR1A | OGFRL1 1917/4885OPRM1 162/4885OPRK1 135/4885 |
| US-20210330994-A1 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | HCRTR1, HCRTR2, MTNR1A | OGFRL1 1917/4885OPRM1 162/4885OPRK1 135/4885 |
| US-20230293516-A1 | SLEEP DISORDER TREATMENT AND PREVENTION | HCRTR2, HCRTR1, CRY1 | OGFRL1 2565/4885OPRM1 186/4885OPRK1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.